Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Cytodyn Inc (CYDY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.1500 0.0000    0.00%
09:31:00 - Delayed Data. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 82,989
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.1500 - 0.1574
Cytodyn Inc 0.1500 0.0000 0.00%

Cytodyn Inc Company Profile

 
Get an in-depth profile of Cytodyn Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Contact Information

Address 1111 Main Street Suite 660
Vancouver, 98660
United States
Phone 360 980 8524
Fax 360 799 5954

Top Executives

Name Age Since Title
Lishomwa C. Ndhlovu 53 2020 Independent Director
Naoto T. Ueno - - Member of Scientific Advisory Board
Eric D. Mininberg - 2020 Member of Scientific Advisory Board
Karen J. Brunke 71 2022 Independent Director
Stefan Gluck - - Member of Scientific Advisory Board
Kabir Mody - - Member of Scientific Advisory Board
Mazen Noureddin - 2020 Member of Scientific Advisory Board
Stephen M. Simes 71 2022 Independent Director
Hope S. Rugo - 2020 Member of Scientific Advisory Board
Jonah B. Sacha - 2018 Member of Scientific Advisory Board
Ryan M. Dunlap 53 2022 Independent Director
Tanya Durkee Urbach 56 2021 Independent Chairman of the Board
Otto O. Yang - - Member of Scientific Advisory Board
Jordan E. Lake - - Member of Scientific Advisory Board
Jacob P. Lalezari - 2020 CEO & Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CYDY Comments

Write your thoughts about Cytodyn Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Douglas Boggs
Douglas Boggs Jul 28, 2022 7:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lots of chatter about potential partnership with GSK
Douglas Boggs
Douglas Boggs Jan 26, 2022 7:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nadar is voted out by BoD! With his bungling finally out of the way Who knows what the upside is now?
Simon Braun
Simon Braun Jan 11, 2022 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fraud stock
Mustafa Basmaji
Mustafa Basmaji Nov 17, 2021 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nov 16, 2021Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
Douglas Boggs
Douglas Boggs Aug 25, 2021 8:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
Trader John
Trader_John Mar 09, 2021 12:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CytoDyn's Vyrologix Shortens Hospital Stays, Improves Survival in Severe COVID-19 | BioSpace ...In a subset of critical patients
clint malbon
clint malbon Jan 30, 2021 7:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it has huge potential, these are bargain Price's
clint malbon
clint malbon Jan 30, 2021 7:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it has huge potential, these are bargain Price's
Teo Rosengarten
Teo Rosengarten Dec 09, 2020 2:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🆙️🆙️🆙️
Teo Rosengarten
Teo Rosengarten Dec 09, 2020 2:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this will ***after new year
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email